Tolerance of Toxicities of Oral Anticancer Agents among Older Adults with Advanced Cancers – UROP Spring Symposium 2021

Tolerance of Toxicities of Oral Anticancer Agents among Older Adults with Advanced Cancers

Ankita Chittiprolu

UROP Logo

Pronouns: she/her

Research Mentor(s): Yun Jiang, Assistant Professor
Research Mentor School/College/Department: School of Nursing,
Presentation Date: Thursday, April 22, 2021
Session: Session 3 (1pm-1:50pm)
Breakout Room: Room 19
Presenter: 4

Event Link

Abstract

This project is focused on older adults taking oral anticancer agents, OAA. Specifically, capecitabine, an oral chemotherapy, is studied for its use in older adults with advanced cancer. Potentially, older patients may less tolerate OAA toxicities, which will impact the treatment effects and their quality of life. The overarching purpose is to explore the occurrence and effects of OAA toxicity-related symptoms in older adults taking capecitabine using real-world patient data from EHR. We will examine the potential differences in side effects of patients aged more than 65 years and patients less than 65 years from the use of capecitabine. From this data analysis, we will identify determinants through demographics, clinical characteristics, performance status, and the impact of OAA toxicity on treatment plan and performance status changes.

Authors: Ankita Chittiprolu, Yun Jiang
Research Method: Clinical Research

lsa logoum logo